^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD20-targeted CAR-T immunotherapy

    Related drugs:
    Apply
    CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (PRO00037171) (NCT04186520)
    Phase 1/2
    Medical College of Wisconsin
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    05/18/2020
    Primary completion :
    06/30/2026
    Completion :
    06/01/2028
    BCL2
    |
    CAR-20/19-T Cells
    A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05421663)
    Phase 1
    Janssen Research & Development, LLC
    Recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/12/2022
    Primary completion :
    05/29/2026
    Completion :
    12/29/2028
    CD20
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) (CRC-403) (NCT05169489)
    Phase 1/2
    Regeneron Pharmaceuticals
    Active, not recruiting
    Last update posted :
    02/03/2025
    Initiation :
    01/24/2022
    Primary completion :
    08/31/2025
    Completion :
    08/31/2025
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    bbT369
    Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies (NCT05418088)
    Phase 1
    Sumithira Vasu
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    06/30/2022
    Primary completion :
    04/30/2025
    Completion :
    07/31/2026
    CD20 • CD19 • CD22
    |
    CD20 positive
    |
    cyclophosphamide • fludarabine IV • Anti-CD19/CD20/CD22 CAR T-Cells
    Study of IMPT-314 in R/R Aggressive B-cell NHL (MPCT-012L) (NCT05826535)
    Phase 1/2
    ImmPACT Bio
    Recruiting
    Last update posted :
    01/14/2025
    Initiation :
    05/09/2023
    Primary completion :
    06/01/2025
    Completion :
    12/01/2029
    BCL2 • BCL6
    |
    BCL6 rearrangement • BCL2 rearrangement
    |
    rondecabtagene autoleucel (IMPT-314)
    Safety and Efficacy of Anti-CD20/CD30 CAR-T Cells in Subjects with Relapsed/Refractory Lymphoma (NCT06532643)
    Phase 1
    Shanghai First Song Biotechnology Co., LTD
    Recruiting
    Last update posted :
    09/19/2024
    Initiation :
    08/24/2023
    Primary completion :
    09/01/2025
    Completion :
    09/01/2026
    TNFRSF8
    |
    cyclophosphamide • fludarabine IV
    A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas (NCT03277729)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    12/05/2017
    Primary completion :
    03/29/2024
    Completion :
    11/16/2037
    BCL2
    |
    CD20 expression
    |
    cyclophosphamide • fludarabine IV • MB-106
    P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies (NCT06014762)
    Phase 1
    Poseida Therapeutics, Inc.
    Recruiting
    Last update posted :
    06/03/2024
    Initiation :
    04/16/2024
    Primary completion :
    03/01/2029
    Completion :
    03/01/2041
    CD20 • CD5 • FCER2
    |
    CD20 positive
    |
    RG6540 • rimiducid (AP1903)
    A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy (NCT04036019)
    Phase 1
    Shanghai Tongji Hospital, Tongji University Sch...
    Completed
    Last update posted :
    05/28/2024
    Initiation :
    08/20/2019
    Primary completion :
    06/20/2022
    Completion :
    06/20/2022
    CD20
    |
    JNJ-9530
    A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia (NCT05292898)
    Phase 1
    Institute of Hematology & Blood Diseases Hospit...
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    03/14/2022
    Primary completion :
    07/01/2024
    Completion :
    07/01/2026
    CD20 • CD22
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    CAR20(NAP)-T Therapy for B Cell Lymphoma (CARMA-01 Study) (NCT06002659)
    Phase 1/2
    Uppsala University
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    05/01/2024
    Primary completion :
    12/30/2027
    Completion :
    12/30/2027
    CD20
    |
    cyclophosphamide • fludarabine IV • ELC-301
    Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1) (NCT03870945)
    Phase 1/2
    Miltenyi Biomedicine GmbH
    Active, not recruiting
    Last update posted :
    04/30/2024
    Initiation :
    02/25/2019
    Primary completion :
    12/17/2020
    Completion :
    12/31/2025
    BCL2 • BCL6
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    zamtocabtagene autoleucel (MB-CART2019.1)
    Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU) (NCT04844866)
    Phase 2
    Miltenyi Biomedicine GmbH
    Recruiting
    Last update posted :
    04/30/2024
    Initiation :
    08/18/2021
    Primary completion :
    12/31/2024
    Completion :
    07/31/2027
    BCL2 • CD19 • BCL6
    |
    CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    gemcitabine • Rituxan (rituximab) • oxaliplatin • bendamustine • Polivy (polatuzumab vedotin-piiq) • zamtocabtagene autoleucel (MB-CART2019.1)
    MB-CART20.1 Lymphoma (NCT03664635)
    Phase 1/2
    Miltenyi Biomedicine GmbH
    Active, not recruiting
    Last update posted :
    04/23/2024
    Initiation :
    09/25/2018
    Primary completion :
    09/30/2024
    Completion :
    09/30/2024
    CD20
    |
    MB-CART20.1
    An Evaluation of LY007 Cell Injection for r/r B-NHL (NCT06364852)
    Phase 1
    Ruijin Hospital
    Recruiting
    Last update posted :
    04/15/2024
    Initiation :
    12/25/2021
    Primary completion :
    08/31/2024
    Completion :
    05/31/2026
    CD20
    |
    CD20 expression
    |
    LY007
    Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NatHaLi-01) (NCT05607420)
    Phase 1/2
    Cellectis S.A.
    Recruiting
    Last update posted :
    03/01/2024
    Initiation :
    11/01/2022
    Primary completion :
    11/01/2027
    Completion :
    11/01/2027
    BCL2 • BCL6 • CD22
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Campath (alemtuzumab) • UCART20x22
    An Evaluation of LY007 Cell Injection for r/r B-NHL (NCT06279611)
    Phase 1
    Shanghai Longyao Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    12/25/2021
    Primary completion :
    08/31/2024
    Completion :
    05/31/2026
    CD20
    |
    CD20 expression
    |
    LY007
    Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL (NCT04697940)
    Phase 1/2
    Han weidong
    Recruiting
    Last update posted :
    02/07/2024
    Initiation :
    12/15/2020
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    BCL2 • CCND1 • BCL6
    |
    Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
    |
    cyclophosphamide • decitabine • fludarabine IV
    Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL (MB106-CD20-001) (NCT05360238)
    Phase 1/2
    Mustang Bio
    Recruiting
    Last update posted :
    12/20/2023
    Initiation :
    05/24/2022
    Primary completion :
    09/01/2026
    Completion :
    09/01/2026
    BCL2 • CD20 • BCL6
    |
    CD19 positive • CD20 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    MB-106
    Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04007029)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    10/06/2023
    Initiation :
    10/04/2019
    Primary completion :
    08/01/2024
    Completion :
    08/01/2025
    CD20 • CD8 • CD4
    |
    CD19 expression
    |
    cyclophosphamide • fludarabine IV • Actemra IV (tocilizumab) • cyclophosphamide intravenous
    Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT05768529)
    Phase 1/2
    Shanghai Unicar-Therapy Bio-medicine Technology...
    Recruiting
    Last update posted :
    09/21/2023
    Initiation :
    03/28/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2026
    IL6
    |
    CD20 positive • CD20 negative
    |
    cyclophosphamide • U16
    CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (NCT05094206)
    Phase 1
    Medical College of Wisconsin
    Active, not recruiting
    Last update posted :
    08/23/2023
    Initiation :
    06/30/2022
    Primary completion :
    02/01/2025
    Completion :
    02/01/2026
    BCL2
    |
    CAR20.19.22 T
    Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell Lymphoma (NCT05318963)
    Phase 1
    Qiu Lugui
    Recruiting
    Last update posted :
    08/03/2023
    Initiation :
    03/14/2022
    Primary completion :
    06/30/2024
    Completion :
    06/30/2026
    CD20 • CD22
    |
    CD19 expression
    |
    cyclophosphamide • LCAR-AIO
    A Study of C-CAR066 in Subjects With r/r Diffuse Large B Cell Lymphoma Who Received CD19 CAR-T Therapy (NCT04316624)
    Phase 1
    Institute of Hematology & Blood Diseases Hospital
    Completed
    Last update posted :
    07/19/2023
    Initiation :
    09/29/2019
    Primary completion :
    02/08/2023
    Completion :
    02/08/2023
    CD20
    |
    CD20 positive
    |
    JNJ-9530
    A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (ELEVATION) (NCT05800977)
    Phase 1b/2
    Cellular Biomedicine Group Ltd.
    Recruiting
    Last update posted :
    04/06/2023
    Initiation :
    02/22/2023
    Primary completion :
    03/31/2027
    Completion :
    03/31/2027
    BCL2 • CD20 • CD19 • BCL6
    |
    CD20 positive • CD20 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement
    |
    prizloncabtagene autoleucel (JNJ-4496)
    Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL (NCT04030195)
    Phase 1/2
    Precision BioSciences, Inc.
    Completed
    Last update posted :
    01/31/2023
    Initiation :
    03/24/2020
    Primary completion :
    06/24/2021
    Completion :
    06/24/2021
    CD20
    |
    cyclophosphamide • fludarabine IV • PBCAR 20A
    CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients (NCT04260945)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Completed
    Last update posted :
    03/08/2022
    Initiation :
    03/10/2020
    Primary completion :
    10/10/2021
    Completion :
    02/10/2022
    CD20 • CD19
    |
    CD20 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • YTS101
    CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients (NCT04260932)
    Phase 1
    Hebei Yanda Ludaopei Hospital
    Completed
    Last update posted :
    03/08/2022
    Initiation :
    03/01/2020
    Primary completion :
    05/10/2021
    Completion :
    09/10/2021
    CD20 • CD19
    |
    CD20 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • YTS101
    CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. (NCT04697290)
    Phase 1
    Beijing Tsinghua Chang Gung Hospital
    Suspended
    Last update posted :
    02/14/2022
    Initiation :
    03/10/2022
    Primary completion :
    03/10/2023
    Completion :
    06/10/2023
    CD20 • CD19
    |
    CD20 positive • CD19 expression
    |
    cyclophosphamide • fludarabine IV • YTS101
    A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NCT05149391)
    Phase 1
    Peking University
    Recruiting
    Last update posted :
    12/08/2021
    Initiation :
    07/20/2021
    Primary completion :
    07/01/2024
    Completion :
    10/01/2024
    BCL2 • BCL6
    |
    CD20 positive
    |
    prizloncabtagene autoleucel (JNJ-4496)
    CAR-T CD19/CD20 for Patients With Advanced CD19/CD20+ B Cell Line Recurrent or Refractory Hematological Malignancies (NCT04700319)
    Phase 1
    PersonGen BioTherapeutics (Suzhou) Co., Ltd.
    Recruiting
    Last update posted :
    03/08/2021
    Initiation :
    04/19/2019
    Primary completion :
    05/01/2021
    Completion :
    06/01/2021
    CD20
    |
    CD20 positive
    |
    CD19/CD20 CAR T-cells
    4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma (NCT04637503)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    11/19/2020
    Initiation :
    11/18/2020
    Primary completion :
    11/19/2020
    Completion :
    12/31/2023
    CD276
    |
    4SCAR-T • GD2, PSMA and CD276 CAR-T
    Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20 (NCT03097770)
    Phase 1/2
    Chinese PLA General Hospital
    Completed
    Last update posted :
    09/02/2020
    Initiation :
    04/01/2017
    Primary completion :
    05/10/2019
    Completion :
    01/31/2020
    CD20
    4SCAR-T Therapy Post CD19-targeted Immunotherapy (NCT04430530)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    06/12/2020
    Initiation :
    06/01/2020
    Primary completion :
    05/31/2023
    Completion :
    12/31/2023
    CD20 • CD38 • CD123 • CD22 • MME • IL3RA
    |
    4SCAR-T
    Multi-CAR-T Cells Targeting B Cell Lymphomas (NCT04429438)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    06/12/2020
    Initiation :
    06/01/2020
    Primary completion :
    07/31/2023
    Completion :
    12/31/2023
    CD19 • CD79B • CD22 • CD70 • ANPEP
    |
    CD19 expression
    |
    multi-CAR-T cell therapy
    Multi-4SCAR-T Therapy Targeting Breast Cancer (NCT04430595)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    06/12/2020
    Initiation :
    06/01/2020
    Primary completion :
    05/31/2023
    Completion :
    12/31/2023
    HER-2
    |
    HER-2 expression • CD44 expression
    |
    4SCAR-T
    The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma (NCT04169932)
    Phase 1
    Shanghai Longyao Biotechnology Inc., Ltd.
    Recruiting
    Last update posted :
    11/20/2019
    Initiation :
    11/22/2019
    Primary completion :
    11/22/2022
    Completion :
    11/22/2022
    CD20
    |
    CD20 expression
    |
    LY007
    CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies (NCT04156178)
    Phase 1
    iCell Gene Therapeutics
    Unknown status
    Last update posted :
    11/12/2019
    Initiation :
    08/01/2018
    Primary completion :
    09/30/2020
    Completion :
    09/30/2020
    CD20
    |
    CD20 expression • CD19 expression
    |
    CD20-CD19 cCAR T cells
    CAR-T Immunotherapy Targeting CD19- ALL (NCT04016129)
    Phase 1/2
    Shenzhen Geno-Immune Medical Institute
    Recruiting
    Last update posted :
    09/19/2019
    Initiation :
    07/15/2019
    Primary completion :
    07/15/2021
    Completion :
    12/15/2023
    CD20 • CD38 • CRLF2 • CD22 • MME • IL3RA
    |
    4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR • 4SCAR-T
    A Clinical Research of CD20-Targeted CAR-T in B Cell Malignancies (NCT02710149)
    Phase 1/2
    Southwest Hospital, China
    Unknown status
    Last update posted :
    06/25/2019
    Initiation :
    03/01/2016
    Primary completion :
    03/01/2020
    Completion :
    03/01/2021
    CD20
    |
    CD20 expression
    CAR-T for R/R B-NHL (NCT03196830)
    Phase 2
    The First Affiliated Hospital of Soochow Univer...
    Unknown status
    Last update posted :
    04/16/2019
    Initiation :
    06/01/2017
    Primary completion :
    05/31/2021
    Completion :
    05/31/2021
    CD20 • TNFRSF8 • CD22
    |
    CAR-T CD19/CD20/CD22/CD30